Clinical Trial Update: Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating the safety and efficacy of a fixed-dose combination (sofosbuvir/velpatasvir/voxilaprevir) for 12 weeks in adults who previously …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Sofosbuvir/Velpatasvir/Voxilaprevir (sofosbuvir/velpatasvir/voxilaprevir)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C Virus Infection | Phase 3 | Status: COMPLETED | Results posted: 2019-04-03